Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005059 · ClinicalTrials.gov registry record · Phase 2

Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
51
Enrollment target
18
Study locations

NCT00005059 is a Phase 2 study of Lung Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 51 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 18 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005059, a Phase 2 study of Lung Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
51 participants
Enrollment target
18
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin and paclitaxel in treating patients who have metastatic or recurrent unresectable non-small cell lung cancer.

Conditions Studied

Lung Cancer

Interventions

  • DRUG carboplatin
  • DRUG paclitaxel

Study Locations (18)

Minnesota

  • CCOP - Duluth - Duluth
  • Mayo Clinic Cancer Center - Rochester
  • CentraCare Clinic - Saint Cloud
  • CCOP - Metro-Minnesota - Saint Louis Park

Iowa

  • CCOP - Cedar Rapids Oncology Project - Cedar Rapids
  • CCOP - Iowa Oncology Research Association - Des Moines
  • Siouxland Hematology-Oncology - Sioux City

Illinois

  • CCOP - Illinois Oncology Research Association - Peoria
  • CCOP - Carle Cancer Center - Urbana

North Dakota

  • Quain & Ramstad Clinic, P.C. - Bismarck
  • CCOP - Merit Care Hospital - Fargo

South Dakota

  • Rapid City Regional Hospital - Rapid City
  • CCOP - Sioux Community Cancer Consortium - Sioux Falls

Arizona

  • CCOP - Scottsdale Oncology Program - Scottsdale

Kansas

  • CCOP - Wichita - Wichita

Michigan

  • Ann Arbor Hematology Oncology - Ypsilanti

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2000-01
Est. Completion 2006-04
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00005059

The ClinicalTrials.gov registry entry for NCT00005059 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which carboplatin is the first listed.

NCT00005059 reports 18 study locations spanning 10 distinct geographic areas - top geographies include Minnesota, Iowa, Illinois.

Frequently Asked Questions

What is clinical trial NCT00005059 about?

NCT00005059 is a clinical study titled "Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin and paclitaxel in treating patients who have metastatic o...

What is the current status of trial NCT00005059?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2000-01. Estimated completion is 2006-04.

What conditions does trial NCT00005059 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00005059?

The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG).

Who is sponsoring clinical trial NCT00005059?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005059 being conducted?

This trial has 18 study locations across Arizona, Illinois, Iowa, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.